Antibodies News and Research

RSS

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.

17 Jun 2014

Findings provide new strategy for developing safe, effective vaccine against strep throat

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, have identified the genes encoding a molecule that famously defines Group A Streptococcus (strep), a pathogenic bacterial species responsible for more than 700 million infections worldwide each year.

12 Jun 2014

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

According to the American Cancer Society, lung cancer is the second most common cancer among men and women and the leading cause of death in the United States. In 2014, it is estimated that 224,210 people will be diagnosed with lung cancer.

11 Jun 2014

$arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM$

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

arGEN-X, a clinical stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a partnership with The Leukemia & Lymphoma Society (LLS) in which both parties will contribute to the funding of a Phase 2 clinical study of the Company's lead candidate, ARGX-110, in patients with refractory Waldenström's macroglobulinemia (WM).

10 Jun 2014

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer.

10 Jun 2014

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients.

10 Jun 2014

Findings add surprising new dimension to understanding of antibody repertoires

As elite soldiers of the body's immune response, B cells serve as a vast standing army ready to recognize and destroy invading antigens, including infections and cancer cells. To do so, each new B cell comes equipped with its own highly specialized weapon, a unique antibody protein that selectively binds to specific parts of the antigen.

10 Jun 2014

Wistar findings suggest means of boosting initial immune response

Your first response to an infectious agent or antigen ordinarily takes about a week, and is relatively weak. However, if your immune system encounters that antigen a second time, the so-called memory response is rapid, powerful, and very effective.

10 Jun 2014

Researchers move closer to establishing link between GAD65 protein and type 1 diabetes

Researchers are a step closer to establishing the link between a protein with a split personality and type 1 diabetes.

10 Jun 2014

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

For years researchers have been developing molecular imaging techniques that visualize hormonally active breast cancer cells-specifically those testing positive for human epidermal growth factor receptor 2 (HER2).

10 Jun 2014

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.

9 Jun 2014

Device used in physics and chemistry reveals dynamics of pervasive pathogen

If you have it, you probably don't know it. Cytomegalovirus, or CMV, is perhaps one of the biggest pathogens you've never heard of-big, both proportionately and epidemiologically.

6 Jun 2014

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Scientists have identified four biomarkers that may help resolve the difficult differential diagnosis between malignant pleural mesothelioma (MPM) and non-cancerous pleural tissue with reactive mesothelial proliferations (RMPs).

6 Jun 2014

Newborn congenital adrenal hyperplasia screening justified

The Swedish neonatal screening programme successfully detected all cases of clinically classified salt-wasting congenital adrenal hyperplasia during a 26-year period, researchers report.

5 Jun 2014

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Researchers at Mayo Clinic have demonstrated in a mouse model that their recently developed synthetic peptide carrier is a potential delivery vehicle for brain cancer chemotherapy drugs and other neurological medications. The findings appear in PLOS ONE.

4 Jun 2014

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

Glenmark Pharmaceuticals S.A (GPSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals Limited, India (GPL), announced the opening of its new cGMP compliant monoclonal antibody manufacturing facility in La Chaux-de-Fonds, Switzerland. T

4 Jun 2014

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it has entered into a long-term strategic alliance with Shire Pharmaceuticals.

4 Jun 2014

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev (previously known as ColoAd1) were presented at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

4 Jun 2014

Researchers develop antibodies that reduce liver damage, recovers liver function

A Tainan-based research team from National Cheng Kung University (NCKU) has discovered the pathogenesis of liver fibrosis and developed antibodies that reduce liver damage, inhibit hepatic fibrosis, and recover liver function.

4 Jun 2014

Antibodies News and Research

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Delphi Genetics announces new license agreement for use of StabyExpress technology in food industry

Findings provide new strategy for developing safe, effective vaccine against strep throat

Hunterdon Regional Cancer Center offers immuno-therapy clinical trial for lung cancer

arGEN-X partner with LLS to develop ARGX-110 for patients with refractory WM

Inovio evaluates responses of immunotherapy product in treating HPV linked head and neck cancer

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Findings add surprising new dimension to understanding of antibody repertoires

Wistar findings suggest means of boosting initial immune response

Researchers move closer to establishing link between GAD65 protein and type 1 diabetes

Antibody-based molecular imaging agent offers hope for novel breast cancer treatments

Actinium's Chairman to discuss role of alpha-particle radiopharmaceuticals at SNMMI Annual Meeting

Device used in physics and chemistry reveals dynamics of pervasive pathogen

Biomarkers help resolve differential diagnosis between MPM and non-cancerous pleural tissue

Newborn congenital adrenal hyperplasia screening justified

Synthetic peptide carrier delivers drugs through blood-brain barrier for cancer treatment

Glenmark Pharmaceuticals opens new monoclonal antibody manufacturing facility in Switzerland

arGEN-X, Shire Pharmaceuticals announce long-term strategic alliance in therapeutic antibodies

PsiOxus Therapeutics presents positive study results of anti-cancer vaccine Enadenotucirev at ASCO Annual Meeting

Researchers develop antibodies that reduce liver damage, recovers liver function

From IHC to multiplexing: A practical guide for modern tissue analysis eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo